Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis - Summary - MDSpire

Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis

  • By

  • Enrique Gómez de la Fuente

  • Enrique Herrera

  • Iñigo Martinez-Espronceda Esquerdo

  • David Vidal Sarró

  • Ignasi Figueras-Nart

  • Juan F. Silvestre Salvador

  • Yolanda Gilaberte

  • Sergio Santos Alarcón

  • Esther Serra-Baldrich

  • Monica Munera Campos

  • Rosa M. Moro

  • Silvia Díaz-Cerezo

  • Sebastian Moyano

  • Irene Talavera-Rodríguez

  • Mercedes Núñez

  • April 21, 2026

  • 0 min

Share

Objective:

Consider adding significance of evaluating treatment patterns.

Key Findings:
  • Add context on clinical significance of EASI and IGA scores.
Interpretation:

Elaborate on implications for clinical practice.

Limitations:
  • Expand on potential biases in retrospective studies.
Conclusion:

Reiterate importance of real-world evidence in treatment decisions.

Original Source(s)

Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis

  • by Enrique Gómez de la Fuente, Enrique Herrera, Iñigo Martinez-Espronceda Esquerdo, David Vidal Sarró, Ignasi Figueras-Nart, Juan F. Silvestre Salvador, Yolanda Gilaberte, Sergio Santos Alarcón, Esther Serra-Baldrich, Monica Munera Campos, Rosa M. Moro, Silvia Díaz-Cerezo, Sebastian Moyano, Irene Talavera-Rodríguez, Mercedes Núñez

  • April 21, 2026

Related Content

Ivarmacitinib Eased Refractory PCA: Case Report

Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.

Does Air Pollution Affect Skin Health?

Large systematic review finds consistent associations across conditions but highlights low certainty driven by bias and study heterogeneity.

Ivermectin vs Permethrin for Scabies

Investigators evaluate household-level cure rates in dermoscopy-confirmed cases at day 28.